Equity
$RARE
RARE jumps 12% on first FDA-approved Sanfilippo therapy
RARE jumps 12% on first FDA-approved Sanfilippo therapyUltragenyx Pharmaceutical $RARE surged about 12% after the FDA approved Fayuvi for children with Sanfilippo syndrome type A, a rare and devastati...